Lexeo Therapeutics, Inc.
LXEOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Lexeo Therapeutics, Inc. (LXEO) is listed under Biotechnology. The company carries a $403.6M market cap, placing it firmly in the small-cap category. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Market Cap
$403.6M
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
-4.20
EPS (TTM)
$-1.12
EPS (Fwd)
$-1.22
ROE
-54.8%
ROA
-32.5%
Cash
$193.0M
Total Debt
$7.4M
Free CF
-$67.3M
52W Change
89.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $193.0M in cash comfortably exceeding the $7.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$67.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -54.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $654K (2022) to $0 (2025), a 100% decline worth watching.
Lexeo Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Lexeo Therapeutics, Inc.'s trajectory.